Saturday 17 October 2026
Export NYXH’s income statement to Excel — free account
Nyxoah SA
NYXH Healthcare Medical Instruments & Supplies
Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024. In the quarter to June 2026, revenue grew 486.6%, EPS fell 6.35%, free cash flow grew 4.01% and total debt rose 185.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
1.11
0.08
−6.72%
Follow NYXH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 2 | 2 |
| (106.55%) | (114.43%) | (138.78%) | (124.41%) | ||
| (70.17%) | (66.74%) | (75.37%) | (68.23%) | ||
ROIC |
(105.38%) | (122.99%) | (114.01%) | (117.82%) | |
Return on Tangible Assets |
(435.15%) | (552.43%) | (2,409.92%) | (138.39%) | |
Average Days of Receivables |
285.75 | 271.86 | 216.82 | 174.00 | |
Free Cash Flow per Share |
(2.09) | (2.16) | (2.02) | (1.52) | |
Free Cash Flow |
(78.22) | (82.30) | (87.39) | (86.51) | |
Capital Expenditures |
(4.39) | (4.26) | (3.63) | (4.15) | |
| Other line items | |||||
Cash ROIC |
(75.80%) | (52.55%) | (76.85%) | (30.96%) | |
Accounts Receivable Turnover |
1.13 | 1.50 | 2.14 | 2.97 | |
Accounts Payable Turnover |
0.24 | 0.32 | 0.57 | 0.79 | |
Inventory Turnover |
0.35 | 0.81 | 1.35 | 1.93 | |
Average Days of Payables |
1,749.21 | 1,356.38 | 776.65 | 536.92 | |
Days of Inventory on Hand |
1,111.67 | 460.46 | 267.20 | 157.45 | |
Tax Rate |
0.03 | 0.01 | 0.02 | 0.02 | |
Research and Development Expense of Revenue |
774.65% | 427.39% | 278.87% | 195.25% | |
Selling, General and Administrative Expense of Revenue |
775.57% | 481.65% | 336.90% | 261.55% | |
Share Based Compensation of Revenue |
83.18% | 48.76% | 25.34% | 20.42% | |
Interest Coverage |
(10.78) | (7.25) | (8.83) | (4.39) | |
Operating CF/Net income |
0.81 | 0.77 | 0.86 | 0.74 | |
Depreciation/Fixed assets |
0.83 | 1.11 | 1.36 | 1.53 | |
Capex/Depreciation |
(1.08) | (0.84) | (0.58) | (0.56) | |
Revenue per Share |
0.16 | 0.30 | 0.41 | 0.44 | |
Operating CF per Share |
(1.97) | (2.05) | (1.94) | (1.44) | |
Capex per Share |
(0.12) | (0.11) | (0.08) | (0.07) | |
Capex to Sales |
0.71 | 0.38 | 0.21 | 0.17 |
Columns are period end dates